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ARTICLE
Mutations in SLC34A2 Cause Pulmonary Alveolar Microlithiasis
and Are Possibly Associated with Testicular Microlithiasis
Ayse Corut, Abdurrahman Senyigit, Sibel Aylin Ugur, Sedat Altin, Ugur Ozcelik, Haluk Calisir,
Zeki Yildirim, Ayhan Gocmen, and Aslihan Tolun
Pulmonary alveolar microlithiasis (PAM) is a rare disease characterized by the deposition of calcium phosphatemicroliths
throughout the lungs. We ﬁrst identiﬁed a PAM locus by homozygosity mapping to 4p15, then identiﬁed, by a candidate-
gene approach, the gene responsible for the disease as SLC34A2 (the type IIb sodium-phosphate cotransporter gene),
which is involved in phosphate homeostasis in several organs. We identiﬁed six homozygous exonic mutations in the
seven unrelated patients with PAM we studied. Three of the mutations were frameshifts, one was a chain termination,
one was an amino acid substitution, and one was a deletion spanning the minimal promoter and the ﬁrst exon. Absence
of functional protein product of the gene is compatible with calcium phosphate deposition in alveolar airspaces. We
show that impaired activity of the phosphate transporter is presumably responsible for the microliths and that PAM is
a recessive monogenic disease with full penetrance. Testicular microlithiasis (TM) is a disease that is more common than
PAM. It is often associated with cancer and infertility. Since the gene we identiﬁed is also expressed in testis, we searched
for mutations in subjects with TM. In 2 of the 15 subjects with TM we studied, we identiﬁed two rare variants, one
synonymous and the other noncoding, that are possibly associated with the condition.
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Pulmonary alveolar microlithiasis (PAM [MIM 265100]) is
a rare disease characterized by the deposition of calcium
phosphate microliths throughout the lungs.Most patients
are asymptomatic for several years or even for decades,
and, generally, the diagnosis is incidental to clinical in-
vestigations unrelated to PAM. Cases with early onset or
rapid progression are rare. A “sandstorm-appearing” chest
roentgenogram is a typical diagnostic ﬁnding. The onset
of this potentially lethal disease varies from the neonatal
period to old age, and the disease follows a long-term,
progressive course, resulting in a slow deterioration of
lung functions. A variety of environmental factors have
been suggested as the etiology, and about one-third of the
reported cases are familial (reviewed by Ucan et al.,1 Cas-
tellana et al.,2 and Mariotta et al.3). A report on six related,
affected individuals was the best support for autosomal
recessive inheritance of the disease.4 Testicular microli-
thiasis (TM), in contrast, is not rare; it has a prevalence
of 0.6%–9% in the population.5 It was found to be asso-
ciated with the majority of primary testicular malignan-
cies6 and with ∼1% of male idiopathic infertility cases.7
We identiﬁed the gene responsible for PAM by positional
cloning and subsequent candidate-gene approach. Here,
we describe (1) the localization of the gene in the family
with six affected individuals mentioned above and (2) the
screening of SLC34A2 (the type IIb sodium-phosphate co-
transporter gene) for mutations in patients with PAM and
subjects with TM.
Material and Methods
Subjects
A large consanguineous family4 was used for linkage analysis. A
total of 7 unrelated patients with PAM and 15 men with diffuse
bilateral TM were included in the SLC34A2 mutation screening.
Informed written consent was obtained from all subjects or their
parents. The study was approved by the Committee on Research
with Human Participants at Bog˘azic¸i University.
Linkage Analysis
A genome scan of three brothers with PAM in family 1 (individ-
uals 501, 503, and 504 in the pedigree shown in ﬁg. 1) was per-
formed using the CHLC/Weber Human screening set version 8a.
The set contained 156 polymorphic microsatellite markers that
spanned the human autosomes with an average density of 1 per
25 cM. The positions of the markers were retrieved from the STS
map of GenBank (NCBIMapViewer andUCSCGenomeBrowser).
Those loci exhibiting shared homozygosity were further analyzed
with more densely spaced markers in the family members avail-
able for study. Marker alleles were resolved on 8% denaturing
polyacrylamide gels and were visualized by staining with silver
nitrate.8 Linkage analysis was performed under the assumption
of autosomal recessive inheritance, full penetrance, a disease gene
frequency of 1 in 100,000, consanguinity, equal recombination
frequencies in both sexes, and equal frequencies ofmarker alleles.
PedCheck version 1.1 was used to detect any Mendelian or ge-
notyping errors in the linkage data.9 SimWalk2 version 2.91 was
used for the calculation of multipoint LOD scores and for the
construction of haplotypes, with allowance for the minimum
number of recombination events.10
Figure 1. Partial pedigree diagram and haplotype analysis at 4p15.31-p15.1 for family 1. Haplotypes are shown by differently shaded
bars. Deduced alleles are shown in italics.
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Table 1. Primers for the Ampliﬁcation of
SLC34A2 Exons
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Figure 2. Multipoint linkage analysis at 4p15.31-p15.1 for family 1. The microsatellite markers used in this study are plotted on the
graph.
Mutation Analysis
All 12 coding exons of SLC34A2 and the ﬂanking intronic se-
quences were ampliﬁed with intronic primers (table 1) designed
using Primer3 software. Exon 13 was ampliﬁed as three overlap-
ping fragments: 13a, 13b, and 13c. Each fragment was ampliﬁed
in a 25-ml volume containing 125 ng of genomic DNA, PCR buffer
with 2 mM MgCl2, deoxynucleoside triphosphates (125 mM of
each), Taq DNA polymerase (0.8 U/reaction), and 0.4 mM of the
primer pair under the following cycle conditions: an initial de-
naturation step at 95C for 5 min; followed by 35 cycles for 30 s
at 94C, 30 s of annealing at the appropriate temperature (given
in table 1), and 2 min of elongation at 72C; and a ﬁnal extension
step for 10 min at 72C. The noncoding exon 1 was ampliﬁed for
the family’s patients and parents only. Because of the GC-rich
nature of the region, a GC-Rich PCR System (Roche) containing
0.5-M GC-rich resolution buffer and GC-rich enzyme mix (2 U/
reaction) were used. The 462-bp product was ampliﬁed using the
522-bp product as a template (table 1). PCR ampliﬁcation for the
522-bp product was performed using the protocol stated by the
manufacturer, whereas the cycling conditions for the 462-bp
product were as follows: an initial denaturation step at 95C for
5 min; followed by 35 cycles for 30 s at 94C, 30 s of annealing
at 55C for 5 cycles and 52C for the remaining 30 cycles, and
50 s of elongation at 72C; and a ﬁnal extension step for 10 min
at 72C.
The ampliﬁed fragments were subjected to SSCP, and any frag-
ment exhibiting an aberrant pattern was further investigatedwith
sequence analysis. SSCP analysis was performed on 8% polyacryl-
amide gels with crosslinking ratios of 2%, both with glycerol
(10%) and without glycerol. Sequencing was performed with an
ABI 310 analyzer (Applied Biosystems) at the Department of Mo-
lecular Biology and Genetics, Bog˘azic¸i University.
Results
Linkage Analysis
The genome scan of the three affected brothers in the large
consanguineous family and the subsequent genotyping at
homozygous loci with additional markers in all family
members available for study pointed to a single candidate
locus at chromosome 4p15. We narrowed the gene locus
to a 4.2-Mbp region at 4p15.31-15.2, ﬂanked by markers
D4S1533 and D4S2305. The haplotype data are given in
ﬁgure 1. LOD scores were calculated to assess the signiﬁ-
cance of the results. The multipoint LOD score peaked to
6.0 between D4S3013 and D4S2305 (ﬁg. 2).
Mutation Analysis
The gene locus contained 16 genes, according to National
Center for Biotechnology Information (NCBI) build 35.1.
SLC34A2 stood out as the likely disease gene, since it was
a phosphate transporter (reviewed by Murer et al.11) ex-
pressed strongly in lung.12,13 We analyzed all 12 coding
exons in the patients with PAM by SSCP and performed
subsequent DNA sequence analysis for samples displaying
aberrant patterns. A total of ﬁve homozygous mutations
in the six unrelated patients were identiﬁed (table 2), but
no mutation was detected in the family. All mutations
were predicted to result in loss of function of the protein
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Table 2. Novel SLC34A2 Sequence Variants Identiﬁed in Patients with PAM, Subjects with TM, and a
Normal Control
Phenotype
and Subject(s) Mutation Location
Effect on
Translation
Predicted Consequence
on Protein
PAM:
1 c.[6773_6588del][6773_6588del] Promoter exon 1 … Not synthesized
3 and 5 c.[114delA][114delA] Exon 3 Frameshift Truncation
7 c.[226CrT] [226CrT] Exon 3 p.Q76X Truncation
6 c.[316GrC][316GrC] Exon 4 p.G106R Substitution
2 c.[1328delT][1328delT] Exon 11 Frameshift Truncation
4 c.[1342delG][1342delG] Exon 12 p.V448X Truncation
TM:
4 c.[T552C][-] Exon 6 p.I184I Aberrant splicing?
6 c.[*27GrT][-] 3′ UTR Unknown Unknown
Normal:
30 c.[989CrT][-] Exon 9 p.T330M Substitution
product of the gene. Mutations c.114delA and c.1328delT
resulted in the shift of the translational reading frame and
the truncation of the protein 7 and 5 codons downstream,
respectively, whereas c.1342delG led to immediate trun-
cation. c.226rT (p.Q76X) created a premature termina-
tion codon. The remaining mutation was c.316GrC,
which substituted an arginine for glycine—a basic residue
for a polar, uncharged one. The glycine residue is con-
served across species (chimpanzee, mouse, dog, and
chicken). While analyzing the normal controls, we iden-
tiﬁed the novel variant c.989CrT (p.T330M) in a single
chromosome in an unaffected female. Threonine is re-
placed with methionine (substituting a polar residue with
a nonpolar one), most likely inactivating the protein. The
residue is conserved in chimpanzee and mouse but is sub-
stituted with serine in dog and chicken.
Having failed to identify the putative mutation in the
family despite sequence analysis of the coding exons, we
analyzed exon 1 and the ﬂanking sequences by direct se-
quence analysis of a seminested PCR product. A deletion
of 186 nt was identiﬁed. The sequences ﬂanked by copies
of hexamer GGCAGG, together with one of the copies,
had been lost. The deletion spanned the 40-bp noncoding
exon and the minimal promoter.14
Moderate expression of SLC34A2 in testis12,13 prompted
us to search for mutations in men with diffuse bilateral
TM. We identiﬁed two rare variants in the heterozygous
state in 2 of the 15 subjects with TM studied (table 2). The
ﬁrst variant was c.552TrC, a synonymous TrC conver-
sion in exon 5. The nucleotide residue is conserved in
chimpanzee but, intriguingly, is a C in mouse, dog, and
chicken. The second variant was noncoding: c.*27GrT, a
GrT transversion 27 nt downstream of the termination
codon. The residue is conserved in chimpanzee; however,
the sequences downstream of termination are not con-
served at all among other species. Although the second
variant was not found in any other individual studied, the
ﬁrst was carried by two individuals in the normal group.
None of the mutations or rare variants we identiﬁed
had been reported previously. All identiﬁed variants that
were not predicted to truncate the protein product (i.e.,
c.316GrC, c.989CrT, c.552TrC, and c.*27GrT) were
screened in 7 unrelated patients with PAM, 15 subjects
with TM, and a control group of 105–123 individuals, to
achieve at least 80% power to distinguish a normal se-
quence variant.15 This population control group com-
prised anonymized, unrelated individuals randomly cho-
sen from our Turkish DNA collection.
Discussion
We localized the gene responsible for PAM in a large family
and identiﬁed homozygous mutations in SLC34A2 in all
patients studied. Six mutations presumably affected the
protein product, whereas the remaining mutation abol-
ished gene expression. That mutation was a 186-bp de-
letion that possibly resulted from an ancestral unequal
crossover at two copies of a hexamer. There are four copies
of the hexamer within a 424-bp region around the exon,
all with the same orientation, but no function has been
proposed for it.
In contrast with the predicted severe effects of the iden-
tiﬁed mutations on the protein product of the gene or
on the expression of the gene, the patients with PAM
had mild clinical phenotypes, with the exception of the
smokers (table 3). The lack of a genotype-phenotype cor-
relation was supported also by the variation in age at onset
among the affected members of the large family. The gen-
eral clinical course of PAM seems to be that microliths
begin forming early in childhood, but clinical symptoms
arise much later, and lung deterioration is very slow in
nonsmokers.
SLC34A2 has 13 exons, the ﬁrst one noncoding, and
encodes a 2,280-nt mRNA and a 690-aa protein. It is a
member of the solute carrier family SLC34A that plays a
major role in the homeostasis of inorganic phosphate. The
gene is expressed most strongly in fetal and adult lung;
therefore, it has been suggested that the gene has an im-
portant physiological function in lung. It was shown to
be expressed in lung only in alveolar type II cells, which
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Table 3. Clinical Features of Patients with PAM
Family
and Patient Sex
Age (years) at
Clinical
Course Comment(s)
Appearance
of Symptoms
Last
Visit
Family 1:
307, or 1 M 25 34 Severe Heavy smoker
403 M 7 17 Moderate Smoker; progressive roentgenographic changes
402 M 3 13 Slow …
501 M … 17 Asymptomatic Received diagnosis at age 11 years4
503 M … 15 Asymptomatic Received diagnosis at age 9 years4
504 M … 11 Asymptomatic Received diagnosis at age 5 years4
Family 2:
2 M 21 24a Slow Died of lung infection
Family 3:
3 F … 38 Asymptomatic PAM diagnosed incidentally
Family 4:
4 M 26 39 Slow …
Family 5:
5 F 9 17 Improving Receiving treatment with disodium ethidronate16
Family 6:
6 F 5 22 Stable Receiving treatment with disodium ethidronate16
Family 7:
7 F 29 35 Slow …
a Deceased.
are responsible for surfactant production.17,18 This ﬁnding
led to the proposal that the function of the gene protein
was to uptake liberated phosphate from the alveolar ﬂuid
for surfactant production, the major components of
which are phospholipids. This hypothesis is in line with
the observation that the microliths are located in alveolar
airspaces.19 In addition, calciﬁcations along interlobular
septa, bronchovascular bundles, and pleura were ob-
served.19 The ﬁnding that mutations in the gene are re-
sponsible for the disease in all our patients with PAM sug-
gests that phosphate uptake in lung is performed mainly
by this gene’s protein product.
In light of our ﬁndings, it is certain that PAM is a re-
cessively inherited disease and is not caused by environ-
mental factors. It has full penetrance, since none of the
unaffected members of the large family was homozygous
for the disease haplotype. Genetic heterogeneity is not
likely for this disease, since we identiﬁed mutations in all
seven unrelated patients studied. The highest incidence
of the disease has been reported in Turkey.1 We did not
ﬁnd a common mutation among our patients. Only the
mutations in patients 3 and 5 were the same, and those
patients originated from different parts of the country.
Thus, it is more likely that the mutation is recurrent rather
than identical by descent. We propose that the high in-
cidence of the disease in Turkey is due to the high pro-
portion of consanguineous marriages. Indeed, all patients
carried homozygous mutations, in accordance with iden-
tity by descent.
Moderate expression of SLC34A2 in testis12,13 prompted
us to search for mutations in men with diffuse bilateral
TM, to investigate any role of the gene in the etiology of
the condition. The two rare variants we identiﬁed could
not be assigned as mutations as readily as could those
found in patients with PAM. Further studies are needed
to determine whether they have any effect on the ex-
pression of the gene or on its protein product. Both var-
iants were associated with infertility, but only c.*27GrT
was associated with a tumor. Variant c.552TrC created a
hexamer that has been proposed to be an exonic splicing
enhancer that plays an important role in constitutive or
alternative splicing.20,21 Alternative splicing would de-
crease the number of full transcripts in the cell and, sub-
sequently, decrease the activity of the gene. The other TM
variant (c.*27GrT) was noncoding, located downstream
of the translational termination codon. The residue is con-
served in chimpanzee; however, the sequences down-
stream of termination have not been conserved at all
among other species. We investigated whether the variant
had an effect on the conformation of the mRNA, using
the program RNA2 (GeneBee Molecular Biology Server),
but we did not obtain a strongly supportive result. There-
fore, we are unable to propose any possible effect of the
variant on mRNA stability. In addition, the fact that testis
has a lower temperature than the body temperature raises
the question of whether the altered forms of the mRNA
and the protein would have less effective conformations
at the lower temperature. Whether the variants contribute
in any way to susceptibility to TM, a common condition,
needs to be investigated. We also mention that none of
our seven male patients with PAM had positive ﬁndings
when investigated for TM.
So far, calcium ions have been blamed for the patho-
genesis. Now, it is clear that microlith formation is the
result of phosphate-chelating calcium in the extracellular
ﬂuid.Microliths fromboth patients with PAMand subjects
with TM had been found to be composed of calcium and
phosphate.22,23 The rare variants carried by two of our sub-
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jects with TM indicated that SLC34A2 could be responsible
for the condition, at least in those subjects. It should be
noted that the efﬁciency of SSCP is not 100%; thus, prob-
able variants in other subjects with TM might have es-
caped detection. Also, variants could possibly be located
in those regions of the gene we did not analyze. Thus, 12/
15 of the subjects could possibly be carrying variants. The
prevalence of TM in the Turkish population is reported as
2.4% in 17–42-year-old healthy men, which is within the
range reported for other populations.24
This is the ﬁrst report of a pathological role of SLC34A2.
Although defects in the gene lead to calcium phosphate
deposits, defects in the other members of the gene fam-
ily—namely, SLC34A1 and SLC34A3—result in hypo-
phosphatemia, because those genes are responsible for
phosphate reabsorption in kidney.25,26 Interestingly,
SLC34A2 is also expressed in kidney. We were able to in-
vestigate phosphate uptake in one of our patients (patient
5). The observed value of 92% maximal renal tubular reab-
sorption was within the normal range. Thus, all our ob-
servations together indicate that SLC34A2 does not play
a role in renal reabsorption as important as the role of its
paralogs. Also, serum phosphate levels were normal in all
9 of our 12 patients with PAM, and none of the 10 patients
investigated had calciﬁcations in the kidneys.
The identiﬁcation of the gene responsible for calcium
phosphate deposition in lung has broad implications, be-
cause the same gene might be responsible also for calci-
ﬁcations in several other tissues. This hypothesis is based
on two observations. First, SLC34A2 is expressed also in
kidney, pancreas, prostate, ovary, small intestine, mam-
mary gland, liver, and placenta,12,13 and idiopatic isolated
calciﬁcations of some of these organs are well docu-
mented. Second, calcium deposits were reported in ad-
ditional organs in some patients with PAM: pleura and
kidneys,27 seminal vesicles,28 urethra,29 and gall bladder.29
The possible role of the gene in calciﬁcation in various
tissues as well as in diseases with clinical manifestations
resembling PAM and TM can now be investigated. Partic-
ularly interesting would be prostate microlithiasis and
mammary calciﬁcations, sincemalignancies are associated
with them. Microcalciﬁcations associated with malignant
breast lesions are more commonly calcium phosphate30
than calcium oxalate. The former was reported to enhance
mitogenesis in both mammary epithelial cells and breast
cancer cell lines.31
The identiﬁcation of the gene responsible for PAM will
facilitate genetic diagnosis of isolated cases. Also, early
diagnosis in asymptomatic individuals in affected families
would be most conveniently performed by a genetic test.
Several therapeutic approaches have been applied with no
knowledge of the molecular basis of PAM. Now, there is
hope for the development of gene therapy. Since the gene
encodes an integral membrane protein, as does the cystic
ﬁbrosis transmembrane regulator gene, strategies devel-
oped for gene therapy for cystic ﬁbrosis might beneﬁt pa-
tients with PAM in the future.
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